SCHEDULE 13G: Soleus Capital Entities Disclose 5.0% Passive Stake in NovoCure Limited
Beneficial Ownership Report
Soleus Capital Master Fund, L.P. and its affiliated entities have reported a passive beneficial ownership of 5.0% in NovoCure Limited, totaling 5,521,414 ordinary shares.
Summary
- Soleus Capital Master Fund, L.P., along with its related entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 5,521,414 ordinary shares of NovoCure Limited.
- This aggregate amount represents 5.0% of NovoCure Limited's outstanding ordinary shares.
- The percentage is calculated based on 109,915,429 ordinary shares of NovoCure Limited outstanding as of February 21, 2025, as reported in the Issuer's Annual Report on Form 10-K.
- The reporting persons share both voting and dispositive power over all 5,521,414 shares.
- The filing is a Schedule 13G, indicating a passive investment, and the reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, factual filing regarding beneficial ownership disclosure.
Management Comments
- Guy Levy, as Managing Member for the various Soleus Capital entities, certified that, to the best of his knowledge and belief, the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive ownership stake by institutional investors, which can be viewed as a vote of confidence or simply a portfolio allocation.
Key Dates
| Date | Description |
|---|---|
| 2025-02-21 | Date as of which 109,915,429 ordinary shares of NovoCure Limited were reported outstanding in the Issuer's Form 10-K. |
| 2025-02-27 | Date NovoCure Limited's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, was filed with the SEC. |
| 2025-03-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-04-01 | Date of signing for the Schedule 13G and the Joint Filing Agreement. |
Keywords
NovoCure Limited, Soleus Capital Master Fund, Beneficial Ownership, SEC Filing, Schedule 13G, Passive Investment, Ordinary Shares, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.